×
Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

US Chorea Market

ID: MRFR/HC/18064-HCR
100 Pages
Garvit Vyas
October 2025

US Chorea Market Research Report By Distribution Channel (hospitals, clinics, diagnostic centers, drug stores, pharmacies, others), By Symptoms (involuntary muscle movements, milkmaid's grip, speech problems, seizures), By End User (clinics, hospitals, ambulatory surgical centers, others), By Product Type (Medication, Surgery therapy) and By Treatment (Medical care, Surgical care) - Forecast to 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

US Chorea Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF

US Chorea Market Summary

As per MRFR analysis, the US chorea market Size was estimated at 168.0 USD Million in 2024. The US chorea market is projected to grow from 179.41 USD Million in 2025 to 346.0 USD Million by 2035, exhibiting a compound annual growth rate (CAGR) of 6.79% during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The US chorea market is experiencing a positive trajectory driven by advancements in treatment and increased awareness.

  • Rising awareness and diagnosis of chorea disorders are contributing to a growing patient population.
  • Advancements in treatment options are enhancing the quality of life for patients with chorea.
  • Regulatory changes and support are facilitating the introduction of innovative therapies in the market.
  • The increasing prevalence of chorea disorders and growing investment in neurological research are key drivers of market growth.

Market Size & Forecast

2024 Market Size 168.0 (USD Million)
2035 Market Size 346.0 (USD Million)

Major Players

Teva Pharmaceutical Industries Ltd (IL), Bristol-Myers Squibb Company (US), AbbVie Inc (US), Novartis AG (CH), Roche Holding AG (CH), Sanofi (FR), Pfizer Inc (US), Eli Lilly and Company (US)

US Chorea Market Trends

The chorea market is currently experiencing notable developments, driven by a combination of increasing awareness and advancements in treatment options. The prevalence of chorea, often associated with conditions such as Huntington's disease, has led to a growing demand for effective therapies. Healthcare providers are focusing on improving patient outcomes through innovative approaches, which may include pharmacological treatments and supportive therapies. As a result, stakeholders in the chorea market are actively seeking to enhance their product offerings and expand their reach within the healthcare system. Moreover, the regulatory landscape appears to be evolving, with potential changes aimed at facilitating faster approval processes for new therapies. This shift may encourage pharmaceutical companies to invest in research and development, ultimately leading to a wider array of treatment options for patients. Additionally, the emphasis on personalized medicine suggests that future therapies may be tailored to individual patient needs, enhancing efficacy and safety. Overall, the chorea market is poised for growth, driven by innovation and a commitment to improving the quality of life for those affected by this condition.

Rising Awareness and Diagnosis

There is an increasing recognition of chorea and its associated conditions, leading to more accurate diagnoses. This trend is likely to enhance the demand for treatment options as healthcare professionals become more adept at identifying symptoms and referring patients for appropriate care.

Advancements in Treatment Options

Innovations in pharmacological therapies are emerging, providing new hope for patients. These advancements may include novel medications that target specific pathways involved in chorea, potentially improving patient outcomes and quality of life.

Regulatory Changes and Support

The regulatory environment is evolving, with potential reforms aimed at streamlining the approval process for new therapies. This could encourage greater investment in research and development, fostering a more dynamic chorea market.

US Chorea Market Drivers

Technological Innovations in Treatment

Technological advancements in the development of therapies for chorea disorders are significantly influencing the chorea market. Innovations such as gene therapy and targeted drug delivery systems are emerging as potential game-changers in treatment efficacy. For instance, recent breakthroughs in gene editing technologies may offer new avenues for addressing the underlying genetic causes of chorea. The market for neurological therapeutics is projected to reach approximately $100 billion by 2026, highlighting the financial potential of these innovations. Furthermore, the integration of digital health solutions, including telemedicine and mobile health applications, is enhancing patient monitoring and treatment adherence. These technological developments not only improve patient outcomes but also attract investment and interest from pharmaceutical companies, thereby fostering a dynamic environment within the chorea market.

Increased Focus on Patient-Centric Care

The shift towards patient-centric care models is reshaping the landscape of the chorea market. Healthcare providers are increasingly prioritizing the needs and preferences of patients, leading to more personalized treatment approaches. This trend is particularly relevant for chorea disorders, where symptoms can vary widely among individuals. The emphasis on patient engagement and shared decision-making is likely to drive demand for tailored therapies and support services. Furthermore, organizations advocating for patients with chorea are gaining traction, raising awareness and promoting access to care. This focus on patient-centricity may also influence regulatory policies, encouraging the development of treatments that align with patient needs. As a result, the chorea market is expected to evolve in ways that enhance patient satisfaction and improve overall health outcomes.

Increasing Prevalence of Chorea Disorders

The rising incidence of chorea disorders in the US is a notable driver for the chorea market. Conditions such as Huntington's disease and Sydenham's chorea are becoming more recognized, leading to a greater demand for diagnostic and therapeutic solutions. Recent estimates suggest that approximately 5-10 individuals per 100,000 are affected by Huntington's disease alone, indicating a substantial patient population. This growing prevalence necessitates enhanced healthcare resources and innovative treatment options, thereby stimulating market growth. As awareness increases, healthcare providers are more likely to invest in advanced diagnostic tools and therapies, further propelling the chorea market. The need for effective management strategies for these disorders is likely to drive research and development efforts, ultimately benefiting patients and healthcare systems alike.

Growing Investment in Neurological Research

The increasing investment in neurological research is a critical driver for the chorea market. Government and private sector funding for studies focused on chorea and related disorders is on the rise, reflecting a commitment to understanding these complex conditions. In 2025, funding for neurological research in the US is expected to exceed $30 billion, with a portion allocated specifically for chorea-related studies. This influx of capital is likely to accelerate the development of new therapies and diagnostic tools, addressing unmet medical needs. Additionally, collaborations between academic institutions and pharmaceutical companies are becoming more common, fostering innovation and expediting the translation of research findings into clinical applications. As a result, the chorea market stands to benefit from enhanced research capabilities and a more robust pipeline of treatment options.

Regulatory Support for Innovative Therapies

Regulatory support for innovative therapies is a significant driver impacting the chorea market. The US Food and Drug Administration (FDA) has implemented various initiatives aimed at expediting the approval process for novel treatments, particularly those addressing rare neurological disorders. This regulatory environment encourages pharmaceutical companies to invest in research and development for chorea therapies, as the pathway to market entry becomes more streamlined. In recent years, the FDA has granted breakthrough therapy designations to several promising candidates targeting chorea symptoms, indicating a favorable outlook for new treatments. This supportive regulatory framework not only enhances the attractiveness of the chorea market for investors but also holds the potential to bring much-needed therapies to patients more rapidly. As a result, the market is likely to experience growth driven by the introduction of innovative solutions.

Market Segment Insights

By Type: Huntington's disease (Largest) vs. Drug-induced Chorea (Fastest-Growing)

In the US chorea market, Huntington's disease is the largest segment, commanding a significant share due to its prevalence and the continuous need for effective treatments. This segment accounts for the majority of the market, driven by increasing awareness and diagnosis rates, leading to rising demand for therapeutic options that cater to symptomatic management and disease progression. On the other hand, drug-induced chorea is identified as the fastest-growing segment, propelled by the rise in drug use that can lead to this condition. The market is witnessing a surge in research and development efforts focused on creating treatment solutions. Additionally, awareness campaigns and improved diagnostic techniques are expected to contribute to the growth of this segment, further diversifying the treatment landscape within the chorea market.

Huntington's disease (Dominant) vs. Drug-induced Chorea (Emerging)

Huntington's disease stands as the dominant force in the US chorea market, characterized by a well-established patient population and ongoing advancements in treatment methodologies. The segment is supported by a robust pipeline of therapies aimed at alleviating symptoms and improving the quality of life for affected individuals. Conversely, drug-induced chorea is emerging rapidly, driven by both the side effects of antipsychotic medications and increasing recognition of this phenomenon among healthcare professionals. This segment's growth is underpinned by targeted studies and clinical trials aimed at understanding and managing this condition, indicating a shift towards more comprehensive care as clinicians strive to mitigate drug-related adverse effects.

By Treatment: Medical Care (Largest) vs. Surgical Care (Fastest-Growing)

In the US chorea market, the treatment segment showcases a significant distribution between medical and surgical care. Medical care holds the larger portion of the market as it includes ongoing medication and therapeutic strategies that are crucial for managing chorea symptoms. Conversely, surgical care, while smaller, is gaining traction as a viable option for patients unresponsive to traditional medical treatment, highlighting a shift in treatment paradigms within the market. The growth trends for the treatment segment indicate a robust increase in the adoption of both medical and surgical approaches. The drive toward surgical care is primarily due to advancements in surgical techniques and technologies, which enhance patient outcomes. Additionally, an increasing awareness of chorea and a growing emphasis on early diagnosis contribute to a more proactive approach in treatment, further benefitting both segments of care in the market.

Medical Care: Dominant vs. Surgical Care: Emerging

Medical care in the US chorea market is characterized by established practices and a variety of pharmacological treatments designed to alleviate symptoms and improve quality of life for patients. This segment remains the dominant force due to the longstanding integration of medications, such as dopamine blockers and other neuroleptic agents, which provide essential support for symptoms management. On the other hand, surgical care is an emerging segment that is gaining attention. With innovations in neurosurgical procedures, such as deep brain stimulation, surgical care is presenting new avenues for patients who experience severe symptoms that are not adequately managed by medications. As research into the effectiveness and safety of these procedures progresses, surgical care is likely to see significant growth, marking its position as a crucial alternative treatment option.

By Distribution Channel: Hospitals (Largest) vs. Pharmacies (Fastest-Growing)

In the US chorea market, hospitals represent the largest distribution channel, capturing a significant market share due to their comprehensive services and advanced treatment options. Clinics and diagnostic centers also contribute, though to a lesser extent, indicating their important role in patient diagnosis and management. Drug stores and pharmacies serve as vital points for medication distribution, catering to the outpatient needs of patients, thus supporting their relevance in the overall distribution landscape. The growth trends within this segment reveal a shift towards more pharmacy-based care, particularly as patients seek convenient access to medications and counsel on their use. Pharmacies are emerging as a fastest-growing channel, driven by increasing awareness of chorea and the need for effective management solutions. Additionally, technological advancements and improved logistical frameworks are facilitating better service delivery across all channels, further enhancing market dynamics.

Hospitals: Dominant vs. Pharmacies: Emerging

Hospitals remain the dominant force in the US chorea market distribution channels, primarily due to their capacity to offer specialized care and complex treatment regimens. They possess the necessary infrastructure and resources to manage severe cases effectively, making them essential for patient outcomes. Conversely, pharmacies are recognized as the emerging players, quickly adapting to the rising demand for chorea management solutions. Their accessibility and focus on healthcare services have allowed them to cater to patients’ immediate needs, thus accelerating their growth within the market. The interplay between these segments highlights a trend towards more integrated care, where patients benefit from both hospital services and pharmacy support.

By Symptoms: Involuntary Muscle Movements (Largest) vs. Speech Problems (Fastest-Growing)

In the US chorea market, the symptoms segment is characterized by varied manifestations of the disorder, with involuntary muscle movements taking the largest share. This segment includes conditions like chorea and dystonia, with involuntary muscle movements being the most prevalent, contributing significantly to the overall symptomatology experienced by patients. Speech problems, while currently smaller in market share, have shown remarkable growth, representing a critical area of concern for affected individuals seeking treatment options. The growth trends in this segment are primarily driven by increased awareness and understanding of chorea's impact on lifestyle. Healthcare advancements have led to better diagnosis and management, resulting in a rising demand for effective therapies. The increasing identification of symptoms like seizures and milkmaid's grip is also contributing to the segment's evolution, with more patients being recognized and seeking help, thus expanding the overall market potential.

Involuntary Muscle Movements (Dominant) vs. Speech Problems (Emerging)

Involuntary muscle movements are the dominant symptom in the US chorea market, reflecting the most recognized manifestation of chorea disorders. This symptom is characterized by uncontrolled, irregular movements that can impact daily functionalities, significantly affecting patients' quality of life. On the other hand, speech problems are emerging as a significant concern as they can severely hinder communication abilities. Patients experiencing this symptom often require specialized speech therapy and interventions to improve their quality of life. The differentiation between these manifestations illustrates the diverse nature of chorea symptoms, with involuntary muscle movements leading in recognition and prevalence, while speech-related concerns are gaining attention due to their profound impact on social interaction and communication.

By End-Users: Hospitals (Largest) vs. Clinics (Fastest-Growing)

In the US chorea market, the distribution of market share among end-users shows that hospitals hold the largest share, primarily due to their capacity to provide comprehensive treatment and access to advanced technologies. Clinics, while smaller in overall share, are rapidly gaining traction thanks to their convenient locations and cost-effectiveness, appealing to a wider range of patients seeking treatment. Growth trends in this segment are primarily driven by the increasing prevalence of chorea and a rising awareness of treatment options among patients. The shift towards outpatient care is helping clinics grow faster, reflecting a broader trend in healthcare where patients prefer receiving care in less intensive settings. Innovations in treatment and supportive therapies also contribute to the segment's expansion.

Hospitals: Dominant vs. Clinics: Emerging

Hospitals play a dominant role in the US chorea market as they are equipped with specialized resources and staff that can cater to complex cases. Their ability to integrate different treatment modalities under one roof allows for a holistic approach to patient care. Conversely, clinics are emerging as a significant force, primarily due to their ability to provide targeted treatments in a more accessible environment. They offer shorter wait times and lower costs, making them an attractive option for patients. This duality in the market highlights the evolving dynamics of healthcare, where both hospitals and clinics will continue to play critical roles in the management of chorea.

Get more detailed insights about US Chorea Market
Request Free Sample

Key Players and Competitive Insights

The chorea market exhibits a dynamic competitive landscape characterized by a blend of innovation, strategic partnerships, and a focus on patient-centric solutions. Key players such as Teva Pharmaceutical Industries Ltd (IL), Bristol-Myers Squibb Company (US), and AbbVie Inc (US) are actively shaping the market through their distinct operational strategies. Teva Pharmaceutical Industries Ltd (IL) emphasizes a robust pipeline of generic and specialty medications, aiming to enhance accessibility and affordability for patients. Meanwhile, Bristol-Myers Squibb Company (US) focuses on innovative therapies, particularly in the realm of neurological disorders, leveraging its research capabilities to address unmet medical needs. AbbVie Inc (US) is strategically positioned through its commitment to research and development, particularly in biologics, which may offer novel treatment options for chorea patients. Collectively, these strategies contribute to a competitive environment that prioritizes innovation and patient outcomes.

The business tactics employed by these companies reflect a concerted effort to optimize operations and enhance market presence. Localizing manufacturing and optimizing supply chains are prevalent strategies aimed at reducing costs and improving efficiency. The competitive structure of the chorea market appears moderately fragmented, with several key players exerting influence while also facing competition from emerging biotech firms. This fragmentation may foster innovation as companies strive to differentiate their offerings in a crowded marketplace.

In October 2025, Teva Pharmaceutical Industries Ltd (IL) announced a strategic partnership with a leading biotech firm to co-develop a novel treatment for chorea, which is expected to enter clinical trials in early 2026. This collaboration underscores Teva's commitment to expanding its therapeutic portfolio and enhancing its competitive edge through innovative solutions. The partnership may also facilitate access to advanced technologies and expertise, potentially accelerating the development timeline for new therapies.

In September 2025, Bristol-Myers Squibb Company (US) launched a new clinical trial aimed at evaluating the efficacy of its investigational drug for chorea management. This initiative reflects the company's ongoing dedication to addressing the needs of patients suffering from this condition. By investing in clinical research, Bristol-Myers Squibb Company (US) not only reinforces its position as a leader in neurological therapies but also demonstrates a proactive approach to meeting regulatory requirements and gaining market approval.

In August 2025, AbbVie Inc (US) expanded its research facilities in the US, focusing on the development of biologics for neurological disorders, including chorea. This expansion is indicative of AbbVie's long-term strategy to enhance its R&D capabilities and foster innovation. By investing in state-of-the-art facilities, AbbVie Inc (US) aims to streamline the drug development process, potentially leading to faster delivery of new therapies to the market.

As of November 2025, the competitive trends in the chorea market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in drug development. Strategic alliances among key players are shaping the landscape, fostering collaboration that enhances research capabilities and accelerates innovation. The shift from price-based competition to a focus on technological advancements and supply chain reliability is evident, suggesting that future competitive differentiation will hinge on the ability to deliver innovative solutions that meet the evolving needs of patients.

Key Companies in the US Chorea Market market include

Industry Developments


Recent developments in the US Chorea Market indicate a dynamic environment, particularly with key players like GW Pharmaceuticals, Bristol Myers Squibb, Acadia Pharmaceuticals, and Sage Therapeutics actively advancing their portfolios. In October 2023, Acadia Pharmaceuticals achieved a landmark approval for its treatment targeting chorea associated with Huntington's disease, marking a significant step in patient care.

Furthermore, Neurocrine Biosciences reported a positive growth trajectory in its market valuation, which has positively impacted investor interest and expanded its R&D efforts. Notably, in March 2022, Bristol Myers Squibb successfully acquired Turning Point Therapeutics, which has implications for its pipeline of neurodegenerative treatments.

On the financial front, Eli Lilly and Company has shown remarkable growth, driven by increased demand for its innovative therapies. Mergers and acquisitions continue to reshape the landscape; in June 2023, Horizon Therapeutics was acquired by Amgen, creating a robust platform to enhance research capabilities in neurological disorders.

Recent government initiatives for funding R&D in neurological diseases have also contributed to an evolving market landscape. Overall, the US Chorea Market demonstrates ongoing advancements and a competitive spirit among leading pharmaceutical companies.

Future Outlook

US Chorea Market Future Outlook

The Chorea Market is projected to grow at a 6.79% CAGR from 2024 to 2035, driven by advancements in treatment options and increasing awareness.

New opportunities lie in:

  • Development of targeted gene therapies for chorea treatment.
  • Expansion of telehealth services for remote patient monitoring.
  • Investment in AI-driven diagnostic tools for early detection.

By 2035, the market is expected to achieve substantial growth and innovation.

Market Segmentation

US Chorea Market Type Outlook

  • Huntington's disease
  • Rheumatic (Sydenham's Chorea)
  • Drug-induced Chorea

US Chorea Market Symptoms Outlook

  • Involuntary muscle movements
  • Milkmaid's grip
  • Speech problems
  • Seizures

US Chorea Market End-Users Outlook

  • Clinics
  • Hospitals
  • Ambulatory surgical centers
  • Others

US Chorea Market Treatment Outlook

  • Medical care
  • Surgical care

US Chorea Market Distribution Channel Outlook

  • Hospitals
  • Clinics
  • Diagnostic centers
  • Drug stores
  • Pharmacies
  • Others

Report Scope

MARKET SIZE 2024 168.0(USD Million)
MARKET SIZE 2025 179.41(USD Million)
MARKET SIZE 2035 346.0(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR) 6.79% (2024 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Million
Key Companies Profiled Teva Pharmaceutical Industries Ltd (IL), Bristol-Myers Squibb Company (US), AbbVie Inc (US), Novartis AG (CH), Roche Holding AG (CH), Sanofi (FR), Pfizer Inc (US), Eli Lilly and Company (US)
Segments Covered Type, Treatment, Distribution Channel, Symptoms, End-Users
Key Market Opportunities Advancements in gene therapy and personalized medicine enhance treatment options in the chorea market.
Key Market Dynamics Rising demand for innovative therapies drives competitive dynamics in the chorea market.
Countries Covered US

Leave a Comment

FAQs

What is the expected market size of the US Chorea Market in 2024?

The US Chorea Market is expected to be valued at 168.0 USD Million in 2024.

How much is the US Chorea Market projected to grow by 2035?

By 2035, the US Chorea Market is projected to reach a value of 351.0 USD Million.

What is the expected CAGR for the US Chorea Market from 2025 to 2035?

The expected CAGR for the US Chorea Market from 2025 to 2035 is 6.928%.

Which distribution channel is projected to generate the highest revenue in the US Chorea Market by 2035?

By 2035, hospitals are projected to generate the highest revenue, with a valuation of 105.0 USD Million.

What market value is attributed to clinics in the US Chorea Market for 2024?

Clinics are attributed a market value of 35.0 USD Million in the US Chorea Market for 2024.

How much growth is expected for drug stores in the US Chorea Market by 2035?

By 2035, drug stores are expected to grow to a market value of 75.0 USD Million.

Who are the key players in the US Chorea Market?

Key players in the US Chorea Market include GW Pharmaceuticals, Bristol Myers Squibb, and Acadia Pharmaceuticals among others.

What is the expected market value for diagnostic centers in 2035?

The expected market value for diagnostic centers in the US Chorea Market by 2035 is 36.0 USD Million.

How much growth is projected for pharmacies in the US Chorea Market by 2035?

Pharmacies are projected to grow to a market value of 65.0 USD Million by 2035.

What challenges and opportunities exist within the US Chorea Market?

The US Chorea Market presents opportunities related to innovative therapies, while challenges include regulatory hurdles and competition among key players.

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓